New drug applications approved by US FDA as of 01 - 15 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Once-weekly treatment with carfilzomib at the higher 70-mg/m2 dose appears to improve survival in patients with relapsed and refractory multiple myeloma (RRMM) compared with the twice-weekly 27-mg/m2 dosing regimen, regardless of patient and disease characteristics, according to data from the phase III ARROW study.
Liquid biopsy may facilitate detection and serial monitoring of multidrug resistance (MDR) in multiple myeloma by analysing multiparticles (MPs) in blood samples of patients, with a recent study showing that MDR markers are found on MPs of stem-cell-like origin.
The once-weekly carfilzomib regimen of Kd70 mg/m2 for relapsed or refractory multiple myeloma (RRMM) is more favourable than the twice-weekly Kd27 mg/m2, as the former is associated with delayed symptom worsening and greater patient-reported convenience and satisfaction, according to a recent study.
The addition of daratumumab (D) to a bortezomib, melphalan, and prednisone (VMP) regimen improved overall survival (OS) in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplantation (ASCT), results of the phase III ALCYONE trial showed.
In the treatment of stem cell transplant-ineligible patients with newly diagnosed multiple myeloma (MM), the addition of clarithromycin to lenalidomide and dexamethasone yields marked improvements in response rates that, however, do not equate to better survival, as shown in the results of the phase III GEM-Claridex trial.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.